The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | 543,575 | 1,036,117 | 708,991 | 1,239,499 |
| Amortization of operating lease rou assets | 15,589 | 14,768 | 14,354 | 27,312 |
| Allowances for expected credit losses | 202,497 | 55,269 | 175,818 | 40,124 |
| Recoveries for expected credit losses | 26,743 | 49,855 | 0 | 94,912 |
| Bad debts written off | - | 0 | - | - |
| Litigation settlement, loss | - | - | - | 0 |
| Depreciation of property, plant and equipment | 28,293 | 28,430 | 29,001 | 54,442 |
| Dividend income | 0 | 360 | 4,192 | 17,560 |
| Fair value loss on investments in equity securities | 0 | -2,722 | 0 | -91,243 |
| Loss arising from settlement of supplier contract dispute | - | 0 | 0 | - |
| Gain on disposal of investments in equity securities | - | -346 | 27,547 | - |
| Loss on lease termination | - | 0 | 0 | - |
| Impairment on property | - | 0 | - | - |
| Share-based compensation | - | 794,770 | 0 | - |
| Operating loss before working capital changes | 323,939 | -190,027 | -521,557 | -1,138,850 |
| Inventories | -9,549 | -330,745 | -208,175 | -173,001 |
| Trade and other receivables | -243,016 | -944,701 | -206,475 | 368,335 |
| Other assets | -249,999 | - | - | - |
| Trade and other payables | 187,891 | -156,034 | -1,114,895 | -112,559 |
| Advance payment from customer | 31 | -2,879 | -84 | -84,531 |
| Operating lease liabilities | -13,993 | -7,700 | -13,410 | -13,401 |
| Tax liabilities | 227 | -42,256 | 2,169 | 17,304 |
| Net cash used in operating activities | -147,671 | 961,062 | -1,237,465 | -1,561,979 |
| Acquisition of investments in equity securities | - | 95 | 9,064 | - |
| Dividend income | 0 | 360 | 4,192 | 17,560 |
| Change in fixed deposits placed with original maturities more than three months | 13,663 | 15,761 | 15,872 | 31,227 |
| Purchase of plant and equipment | 325 | 977 | 5,483 | 30,511 |
| Proceeds from disposal of investments in equity securities | - | 10,756 | 1,020,873 | - |
| Proceeds from settlement of supplier contract dispute | - | 0 | 0 | - |
| Net cash used in investing activities | -13,988 | -5,717 | 994,646 | -44,178 |
| Advance from/ (repayments to) directors | 80,717 | -497 | 34,187 | -1,385 |
| Cash paid for fractional shares in reverse stock split | - | 270 | 0 | 505 |
| Share subscription | - | 267,311 | - | - |
| Deposit payment of finance lease liabilities | 21,008 | - | - | - |
| Net cash generated from/(used in) financing activities | 59,709 | 266,544 | 34,187 | -1,890 |
| Foreign currency translation adjustment | 13,544 | -92,598 | 28,535 | 258,270 |
| Net change in cash and cash equivalents | -88,406 | 1,129,291 | -180,097 | -1,349,777 |
| Cash and cash equivalents, beginning of financial period | 2,486,383 | 1,357,092 | 2,886,966 | - |
| Cash and cash equivalents, end of financial period | 2,397,977 | 2,486,383 | 1,357,092 | - |
BioNexus Gene Lab Corp (BGLC)
BioNexus Gene Lab Corp (BGLC)